The ex vivo enrichment for the CD34 ؉ cell fraction of PBPC, while it retains the capacity to restore haematopoiesis and potentially reduces a contamination by tumour cells, implements a depletion of T cells. To test whether such a setting adversely affects T cell reconstitution, we monitored T cells in four paediatric patients after CD34 
shown to be an effective treatment for high risk malignancies. 1, 2 Peripheral blood mononuclear cells (PBMC) that have been stimulated with G-CSF contain a small fraction of haematopoietic CD34 + stem cells 3, 4 which are able successfully to restore haematopoiesis after myeloablative HD-CTX. 5, 6 The success of such treatment, however, may be hampered by a contamination of the leukapheresis product with residual circulating tumour cells. [7] [8] [9] Therefore, the enrichment of G-CSF stimulated PBMC for CD34
+ cells might be of benefit by reducing the risk of reinfusing vital tumour cells together with the leukapheresis product. 10 This procedure, however, results in an effective depletion of T cells. Since previous evidence suggests that peripheral T cells reinfused together with bone marrow or PBPC significantly contribute to the reconstitution of T cells after myeloablative treatment, [11] [12] [13] T cell depletion may adversely affect T cell regeneration.
14 Recent reports of the kinetics of lymphoid reconstitution after CD34
+ selected autologous and allogeneic PBPC transplantation in children and adults 15, 16 showed that T cell reconstitution was delayed as compared to a rescue with unmanipulated grafts. We hypothesised that high residual thymic activity, as present in early childhood, might allow for a rapid regeneration of T cells in the absence of suppressive factors, such as GVHD, and studied T cell regeneration in four paediatric patients after autologous CD34
+ selected PBPC transplantation. These patients were most homogenous with respect to factors with a potential relevance to the T cell regenerative capacity (see below). The results show an effective and rapid reconstitution of T cells and T cell subsets based on a preferential use of a thymopoietic pathway, indicating that T cell depletion of PBPC by positive selection for CD34 + cells does not per se adversely affect T cell reconstitution in the paediatric age group.
Patients and methods

Patients
The clinical characteristics of the patients are summarised in Table 1 . Care was taken to avoid a variety of combinations of factors with a potential relevance to T cell regenerative capacity. The four consecutively treated patients had similar clinical features. The median age was low (3.5 348 years, range 2-8 years). All had advanced stage malignant tumours, all had been treated with four to six courses of conventional chemotherapy and were in first CR prior to receiving autologous PBPC rescue, and received the same preparative regimen. The engraftment was supported by rh-G-CSF (5-10 g/kg/day s.c.) and was rapid and stable in all four cases. With respect to the post-transplant period none of the patients received extended field radiation therapy and all patients had an uncomplicated post-transplant course, ie no severe infection, no evidence of a tumour relapse, while being investigated for T cell reconstitution.
Composition of CD34
+ selected PBPC
The methods of collection and selection of CD34 + cells have recently been described. 17 Briefly, PBMC were collected in the phase of haematopoietic recovery after cytotoxic treatment and stimulation with rh-G-CSF (5 g/kg/day). PBMC were separated from whole blood using a CS 3000 Plus cell separator (Baxter, Healthcare Fenwal Division, Deerfield, IL, USA). Three leukaphereses were performed on each patient. The PBMC of the first two leukapheresis products were pooled and CD34 + cells were positively selected on a Ceprate SC Stem Cell Concentration System loaded with a CD34-specific biotinylated monoclonal antibody (CellPro, Bothell, WA, USA). This resulted in an enrichment for CD34 + cells of 74%, median (range 51-88%). Before use the cells were cryopreserved in 10% DMSO by controlled rate freezing and stored in liquid nitrogen. The third apheresis product was cryopreserved as a back-up.
With respect to T cells, conventional chemotherapy for neuroblastoma and rhabdomyosarcoma, as given to these patients, invariably induces a severe depletion of T cells (Ref. 18 19 The T cell content of the apheresis product after selection for CD34
+ cells was 1.1%, median (range 0.54-2.9%) with a similar distribution of T cell subsets. The number of reinfused T cells ranged from 0.057 to 0.16 × 10 6 /kg ( Table 1) . The analyses of two-and three-colour studies were performed on a FACScan research software 2.1 (BD). Threecolour analysis was performed to examine T cell subsets within a preselected T cell population, as described. 20 To quantify the proportion of CD4 + and CD8 + cells, CD3 + cells were identified by quadrant analysis of FL3 (PerCP) vs SSC, and gated. These CD3 + cells were then separated into fractions of FL1 (anti-CD4, FITC) and FL2 (anti-CD8, PE) and quantified by quadrant analysis. To quantify CD45RA The absolute lymphocyte count was derived from the differential count of the white blood count. The age-adapted normal values of T cells and T cell subsets were taken from recent standard literature.
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Results
Recovery of total T cells
The median period of time required to recover total T cells (CD3 + ) into the age-adapted normal range was 6 months ( Figure 1 ). By 9 months the T cell count of all four patients was well above the lower limit of 1.0 ϫ 10 9 /l. The proportion of T cells contained within total lymphocytes at the initial evaluations was relatively low (48%, median, at 3 months, 52%, median, at 6 months; normal range 52-85%). Total lymphocytes returned to a normal level by 6 months after treatment (2148/l, median). This reflects the long period of time for T cells to regenerate as compared to other lymphocytes, eg B cells 22 or NK cells. 23 The distribution of T cells expressing the TCR␣␤ and TCR␥␦, which may be altered after autologous BMT 24 + /TCR␥␦ + at 6 months after treatment).
Recovery of T cell subsets
Previous studies of adult autologous and allogeneic BMT and high-dose chemotherapy have consistently shown a long-lasting imbalance of the two major T cell subsets, characterised by a predominance of T cytotoxic/suppressor (Figure 2 ). At this time point CD8
+ cells had returned to baseline levels in three of the four patients (349/l, median, (range 124-580/l); normal range 330-1400/l), while CD4 + cells were below the threshold of normal (141/l, median, (range 24-165/l); normal range 560-2700/l). Between 3 and 6 months the growth rate of CD4
+ cells exceeded that of CD8 + cells; CD4 + cells increased 4.9-fold while CD8
+ cells increased only 1.1-fold (median). This resulted in a normal T helper cell count in three of four patients (Figure 2a) . In all four patients, even in patient 3 with a low T cell count, the CD4/CD8 ratio became normal by 6 months and remained so throughout the observation period (CD4/CD8 ratio 1.7, median, range 1.2-2.5).
Double positive T cells (CD3 + /CD4 + CD8 + ) previously described as occurring in an elevated frequency in the early phase of lymphocyte reconstitution after BMT 27 were less than 2%, median, throughout the observation time. Furthermore, only one of the four patients (patient 3) showed a transient abundance of double negative (CD3 + /CD4 − /CD8 − ) cells (24% at 3 months, 14% at 6 months). 
Distribution of CD45RA + vs CD45RO + T cell subsets
The expression of the high molecular weight isoform of the CD45 antigen (CD45RA) designates T cells as being recently thymus derived. 28 In contrast, T cells with a CD45RO phenotype are considered to represent peripheral memory cells. The distinction of these two CD45 isoforms has allowed discrimination between a thymus-dependent and a thymus-independent pathway of regeneration of the T helper subset. Cells with a CD45RA + phenotype were found to regenerate only in the presence of residual thymus. 20, 29 This pattern was not as stringent in the T cytotoxic/suppressor subset, in which CD45RA
+ cells were regenerated even in the absence of residual thymus. 13, 20, 29 To determine the relative contribution of a thymusdependent and thymus-independent pathway of T cell reconstitution, we sequentially examined the fraction of T cells expressing the CD45RA antigen vs that expressing the CD45RO antigen within the CD4 + and the CD8 + subsets. In the T helper subset, as expected, CD45RO
+ cells represented by far the predominant population at 3 months after treatment, the CD45RA + /CD45RO + ratio being 0.02 (Figure 3a) . At this time point the absolute count of T helper cells in all patients was extremely low (median 141/l, range 24-165/l). The subsequent analysis at 6 months after treatment -a time period at which total CD4 between 3 and 6 months increased 130-fold (from 3/l to 392/l), while that of CD45RO + T helper cells increased only 1.7-fold (from 130/l to 222/l). The subsequent growth rates of CD45RA + cells and CD45RO + cells were similar (1.2-fold vs 0.8-fold and 1.7-fold vs 2.2-fold at 9 and at 12 months, respectively). Unexpectedly, in the T cytotoxic/suppressor subset the expansion of the two CD45 isoform expressing T cell subgroups followed a similar pattern as in CD4
+ cells (Figure 3b) . At 3 months after treatment, the median CD45RA + /CD45RO + ratio of CD8 + cells was 0.07. Between 3 and 6 months after treatment, CD45RA
+ cells increased 9-fold (from 21/l to 190/l, median) while CD45RO
+ cells decreased by 50% (from 295/l to 143/l, median), such that the ratio had turned to normal (median 1.5, range 1.0-1.9). 30 + at 9 and at 12 months, respectively).
Discussion
The positive selection of CD34 + cells in the apheresis product used in this study implies that the amount of peripheral T cells available to contribute to T cell regeneration is reduced as compared to unmanipulated grafts. This, hypothetically, shifts T cell regeneration towards a pathway that employs haematopoietic stem cells and thymopoiesis as the source of reconstitution.
The findings of this study of paediatric patients undergoing HD-CTX with CD34
+ selected PBPC transplantation can be summarised as follows: (1) A period of 6-9 months after treatment was required to quantitatively restore total T cells; (2) A normal distribution of the major T cell subsets was reconstituted rapidly as a combined result of an absence of an overshoot of CD8 + cells and a high growth rate of CD4 + cells; (3) In both major T cell subsets cells with a CD45RA
+ phenotype predominantly expanded. These findings indicate an effective regeneration of T cells, by an effective use of a thymopoietic pathway.
In general, PBPC transplantation might improve T cell regeneration as compared to BMT, as several studies in adults, including patients with leukaemia, NHL, MM and solid tumours, have suggested. [31] [32] [33] [34] These studies also showed a more rapid regeneration of a normal CD4/CD8 ratio. In the autologous setting Talmadge et al 31 observed a normalised CD4/CD8 ratio and an improved cytotoxic and proliferative response even 3 months after PBPC treatment. Also, in HLA-matched allogeneic transplantation, Ö ttinger et al 34 found recipients of PBPC to have a more rapid reconstitution of T cells, which included the regeneration of CD4
+ /CD45RA + naive T helper cells, and to better recover an in vitro response to non-specific and specific stimulatory antigens. The experience with CD34 + selected PBPC transplantation in adults is more limited. Most recently, Bomberger et al 16 investigating patients with NHL showed a delay in recipients of autologous CD34
+ selected PBPC as compared to a control population who received unsorted PBPC. Yet, in their study even the control population failed to recover a normal T cell count by 12 months
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؉ enriched PBPC rescue and T cell recovery in children A Heitger et al 351 after treatment (mean T cell count Ͻ700/l). This finding was in line with multiple previous studies, as recently extensively reviewed by Archimbaud. 35 Thus, there is evidence that in adult PBPC transplantation a depletion of T cells by positive selection of CD34 + cells adversely affects T cell regeneration. In the paediatric age group the knowledge is scarce. Takaue et al 36 investigated 41 children with leukaemia and NHL after unsorted autologous PBPC transplantation and showed abnormally low CD4
+ counts and an inverse CD4/CD8 ratio for Ͼ12 months after treatment. Matsuda et al 15 reported five children having undergone CD34
+ selected PBPC transplantation from allogeneic mismatched donors. The CD3
+ cell counts remained low through the observation time of a maximum of 210 days after transplantion with CD4
+ cells being more severely depressed than CD8 + cells. However, the interpretation of this observation is difficult, since four of the five patients developed acute or chronic GVHD, a factor known to predictably affect T cell regeneration. No recent experience exists with autologous CD34
+ selected PBPC transplantation in children. Thus, the findings of this study, a time period of 6 to 9 months after treatment required to recover normal T cells including normal T cell subsets (a normal CD4/CD8 ratio and a normal CD45RA/CD45RO ratio within the T helper and T cytotoxic/suppressor subset), are promising. They fit well into the range that has been described for paediatric BMT. Foot et al 37 reported a similar time period in paediatric allogeneic HLA-matched BMT, which included T cell-replete and T cell-depleted grafts. Kook et al 38 found that in paediatric allogeneic BMT using T cell-depleted matched unrelated or partially matched donors a period of Ͼ12 months was required to normalise the peripheral T cell number.
Notably, the present study examined a clinically very homogenous group of patients in whom features with a potential adverse effect on T cell regeneration, except the selection process of CD34
+ cells which included a T cell depletion, were absent. First, none of the patients underwent long-lasting extensive conventional chemotherapy prior to and/or irradiation prior to or after HD-CTX with PBPC rescue. Our recent experience with patients who received tandem 39 or triple HD-CTX with unmanipulated PBPC rescue, in line with recent reports, 40, 41 suggests that these factors may adversely affect the bone marrow regenerative capacity including a poor regeneration of T cells (not shown). Second, no severe infection, especially no infection with CMV, occurred during the post-transplant period. CMV infection is known to abrogate a successful T cell regeneration, as exemplified in one patient after CD34 + selected PBSC transplantation. 15 Third, the dose of CD34 + cells was high (median 7.1 × 10 6 CD34 + cells/kg). It has been shown that the period of time required for leukocytic and thrombocytic recovery after PBPC rescue is linked to the number of CD34
+ cells used as a rescue. 17, 42 A high stem cell support may also be critical to a rapid reconstitution of T cells. 31, 32 One recent study by Carabasi et al 43 investigating 10 adult patients after allogeneic CD34 + selected PBPC transplantation using Ͼ9 × 10 6 /kg CD34 + cells, median, showed a rapid normalisation of the CD4/CD8 ratio even by 2 months and a regrowth of CD3 + /CD45RA + cells, indicating a regeneration via newly produced T cells.
Fourth, the age of the patients (2-8 years) was low. It has been shown that age as it reflects residual thymic activity is an important factor for an effective regeneration of T cells, especially of T helper cells. 44 In fact, the rapid T helper cell reconstitution in all patients in this study occurred by a predominant expansion of cells with a naive (CD45RA + ) phenotype, which indicates the effective use of a thymopoietic regenerative pathway. 20, 29 It is intriguing to speculate that in addition to a high number of haematopoietic progenitor cells, young age, as it favours the regeneration via thymus-derived T cells, is a factor that accelerates T helper cell reconstitution.
One interesting finding was that even within the T cytotoxic/suppressor subset CD45RA + cells were the predominantly expanding population. Since CD8 + /CD45RA
+ cells are capable of regenerating even in the absence of thymus 20, 29 and their regeneration is not age-dependent, 13 no conclusion can be drawn as to whether this also indicates a predominant regeneration via thymus-derived CD8 + cells. Irrespective of the hypothetical origin of CD45RA + cells, all patients were able to rapidly, ie by 6 months after treatment, restore a normal distribution of CD45RA
+ and CD45RO
+ cells in both major T cell subsets. A further factor with a potential, but not clarified influence on T cell regeneration was the use of G-CSF in the immediate posttransplant period, which was used to accelerate granulocytic recovery. G-CSF has multiple effects on other haematopoietic cell lineages as well, which include an increment in T cell numbers. 45, 46 Notably, within the observation period of 12 months after treatment, none of the patients experienced infectious problems beyond the expected range. This observation is not trivial since recent evidence suggests that T cell function remains impaired even beyond the quantitative normalization of T cells and T cell subsets. [47] [48] [49] [50] One further problem with respect to T cell function is the restriction of the T cell repertoire after conventional BMT and CD34 + selected PBSC treatment. 16, 51, 52 Yet, a rapid increase of naive T cells, as in these young patients, has been shown to set the scene for the restoration of an unrestricted and diverse T cell repertoire. 53 This needs to be confirmed. Together, the findings show that the setting of HD-CTX and autologous CD34 + selected PBPC transplantation does allow for a an effective and rapid T cell recovery in paediatric patients. Such an approach might be desired in circumstances in which tumour cells potentially contaminate the leukapheresis product and can be removed by a selection for CD34
+ cells, such as in stage IV neuroblastoma. 10 This concept warrants further testing. The extent as to which factors with a potential adverse effect on engraftment (eg a low number of CD34 + cells, partial bone marrow damage by irradiation or prolonged pre-transplant chemotherapy) have a disadvantageous effect also on T cell regeneration remains to be determined.
